HBK Sorce Advisory’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $286K | Sell |
1,489
-239
| -14% | -$41.1K | 0.01% | 520 |
|
|
2026
Q1 | $294K | Hold |
1,728
| – | – | 0.01% | 498 |
|
|
2025
Q4 | $302K | Sell |
1,728
-124
| -7% | -$20.1K | 0.01% | 473 |
|
|
2025
Q3 | $284K | Buy |
1,852
+213
| +13% | +$29.1K | 0.01% | 487 |
|
|
2025
Q2 | $207K | Sell |
1,639
-1
| -0.1% | -$123 | 0.01% | 546 |
|
|
2025
Q1 | $210K | Sell |
1,640
-556
| -25% | -$75.4K | 0.01% | 528 |
|
|
2024
Q4 | $290K | Buy |
2,196
+110
| +5% | +$15.5K | 0.01% | 460 |
|
|
2024
Q3 | $304K | Sell |
2,086
-197
| -9% | -$28.5K | 0.01% | 450 |
|
|
2024
Q2 | $313K | Sell |
2,283
-529
| -19% | -$70.6K | 0.01% | 426 |
|
|
2024
Q1 | $386K | Buy |
2,812
+498
| +22% | +$68K | 0.01% | 397 |
|
|
2023
Q4 | $314K | Buy |
2,314
+1
| +0% | +$122 | 0.01% | 411 |
|
|
2023
Q3 | $283K | Buy |
2,313
+301
| +15% | +$38.3K | 0.01% | 431 |
|
|
2023
Q2 | $255K | Sell |
2,012
-1
| -0% | -$130 | 0.01% | 484 |
|
|
2023
Q1 | $260K | Sell |
2,013
-2,433
| -55% | -$318K | 0.01% | 465 |
|
|
2022
Q4 | $584K | Buy |
4,446
+2,224
| +100% | +$287K | 0.02% | 380 |
|
|
2022
Q3 | $260K | Buy |
2,222
+311
| +16% | +$38.6K | 0.02% | 392 |
|
|
2022
Q2 | $225K | Sell |
1,911
-592
| -24% | -$70.3K | 0.02% | 399 |
|
|
2022
Q1 | $326K | Buy |
2,503
+46
| +2% | +$5.99K | 0.02% | 384 |
|
|
2021
Q4 | $375K | Buy |
2,457
+426
| +21% | +$66K | 0.02% | 396 |
|
|
2021
Q3 | $328K | Buy |
2,031
+44
| +2% | +$7.41K | 0.02% | 411 |
|
|
2021
Q2 | $325K | Buy |
1,987
+370
| +23% | +$57K | 0.02% | 429 |
|
|
2021
Q1 | $243K | Buy |
1,617
+54
| +3% | +$8.58K | 0.01% | 459 |
|
|
2020
Q4 | $237K | Hold |
1,563
| – | – | 0.01% | 436 |
|
|
2020
Q3 | $212K | Buy |
1,563
+49
| +3% | +$6.65K | 0.02% | 410 |
|
|
2020
Q2 | $207K | Sell |
1,514
-537
| -26% | -$68.5K | 0.02% | 402 |
|
|
2020
Q1 | $221K | Buy |
+2,051
| New | +$236K | 0.02% | 343 |
|
|
2019
Q2 | – | Sell |
-2,729
| Closed | -$305K | – | 431 |
|
|
2019
Q1 | $305K | Buy |
2,729
+291
| +12% | +$31.9K | 0.03% | 332 |
|
|
2018
Q4 | $235K | Buy |
2,438
+172
| +8% | +$18.3K | 0.03% | 332 |
|
|
2018
Q3 | $277K | Sell |
2,266
-465
| -17% | -$54.8K | 0.03% | 310 |
|
|
2018
Q2 | $300K | Sell |
2,731
-82
| -3% | -$8.77K | 0.03% | 302 |
|
|
2018
Q1 | $300K | Sell |
2,813
-3
| -0.1% | -$333 | 0.04% | 288 |
|
|
2017
Q4 | $301K | Buy |
2,816
+44
| +2% | +$4.7K | 0.04% | 307 |
|
|
2017
Q3 | $309K | Buy |
2,772
+219
| +9% | +$23.4K | 0.05% | 242 |
|
|
2017
Q2 | $264K | Sell |
2,553
-48
| -2% | -$4.73K | 0.04% | 253 |
|
|
2017
Q1 | $254K | Sell |
2,601
-141
| -5% | -$13.5K | 0.04% | 263 |
|
|
2016
Q4 | $243K | Sell |
2,742
-402
| -13% | -$36.6K | 0.04% | 259 |
|
|
2016
Q3 | $304K | Buy |
3,144
+99
| +3% | +$9.42K | 0.06% | 208 |
|
|
2016
Q2 | $261K | Buy |
3,045
+552
| +22% | +$49.5K | 0.06% | 225 |
|
|
2016
Q1 | $217K | Buy |
+2,493
| New | +$223K | 0.05% | 222 |
|
Other funds holding IBB
WA
AFG
HBK Sorce Advisory's IBB Position: Q2 2026 in Review
HBK Sorce Advisory reduced its iShares Biotechnology ETF (IBB) stake by 14% in Q2 2026, selling an estimated $41.1K and leaving 1,489 shares worth $286K. The position accounts for 0.01% of the portfolio, ranked #520.
HBK Sorce Advisory first reported a position in IBB in Q1 2016 and has held it in 39 quarters since. The position peaked at $584K in Q4 2022. 601 funds tracked by Wall St. Rank hold IBB as of Q2 2026.
- HBK Sorce Advisory held 1,489 shares of iShares Biotechnology ETF worth $286K as of Q2 2026.
- HBK Sorce Advisory sold 239 iShares Biotechnology ETF shares in Q2 2026, an estimated $41.1K.
- iShares Biotechnology ETF made up 0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #520 holding.
- HBK Sorce Advisory first reported a position in iShares Biotechnology ETF in Q1 2016 and has held it in 39 quarters since.
- HBK Sorce Advisory's iShares Biotechnology ETF position peaked at $584K in Q4 2022.
- 601 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.
Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.